Clinical trials: Yellow Fever (Healthy Volunteers)
Yellow Fever (Healthy Volunteers), Biopsy/Methods
Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants
In The main GeKoSkimm trial (= A randomized controlled trial to compare the immunogenicity and skin imprinting of intradermal, subcutaneous and intramuscular yellow fever vaccination) the investigators try to understand whether…
- Trial name
- NCT07636551
- Testing
- Skin punch biopsy, Blood samples
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Yellow Fever, Yellow Fever Immunisation
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
This study is a multi-center, double-blind, placebo-controlled, Phase I study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) in…
- Trial name
- NCT02743455
- Testing
- ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60…
- Trial name
- NCT03342898
- Testing
- YF-17D, TDV
- Where
- 11 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Takeda
Yellow Fever, Healthy Volunteers
Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
The primary objective of the study is to demonstrate the non-inferiority of the antibody response in terms of seroconversion rate 28 days after vaccine administration of one dose of yellow fever vaccine (vYF) compared to the…
- Trial name
- VYF02 (NCT04942210)
- Testing
- Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine
- Where
- 11 sites in United States
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Immune System Responses and Trained Immunity After AS01 Administration, Healthy Adult
Improving Vaccine Protection for Adults
As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines.
- Trial name
- NCT07527247
- Testing
- AS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur)
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Treatment of Acute Yellow Fever Virus Infection
Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans
Yellow Fever is an acute viral hemorrhagic disease caused by the Yellow Fever Virus (YFV), a re-emerging arbovirus transmitted by the same mosquito vector (Aedes aegypti) that transmits Dengue virus (DENV) and Zika virus (ZIKV).
- Trial name
- NCT03776786
- Testing
- TY014, 0.9% Saline
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tysana Pte Ltd
Yellow Fever (Healthy Volunteers)
Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults
The primary objectives of the study are: To describe the safety profile of each of the 3 dosages of vYF and of YF-VAX® within the 28 days post-vaccination and up to the 6 months (Day 180) post-vaccination visit To describe the…
- Trial name
- VYF01 (NCT04142086)
- Testing
- Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Vaccine Response Impaired
Antibiotics and Vaccine Immune Responses Study
The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination.
- Trial name
- AVIRS (NCT06148025)
- Testing
- BCG vaccine, Yellow Fever vaccine, Vancomycin Oral Capsule
- Where
- Australia
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- South Australian Health and Medical Research Institute
Healthy
Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines
It is thought that vaccines trigger innate inflammatory responses to induce antigenspecific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side…
- Trial name
- NCT01765413
- Testing
- Varicella-zoster virus, Yellow Fever Vaccine
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Surrey